This registry is to expand upon existing data sets, to identify patient characteristics and indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis that are undergoing treatment with the commercially available Edwards SAPIEN XT™ Valve, and delivery devices.

Consecutive patient data should be collected at discharge, 30 days and 12 months post-implant. Subsets of patients may undergo additional follow-up.

Inclusion Criteria:

• The SAPIEN XT™ THV is indicated for use in patients with symptomatic aortic stenosis requiring TAVI who have a high risk for operative mortality, or are "non-operable"

Exclusion Criteria:

• Non-valvular or congenital aortic stenosis
• Pre-existing prosthetic heart valve in the Aortic position or a non-calcified aortic valve
• Severe (>3+) mitral insufficiency or aortic regurgitation > 3+
• Active bacterial endocarditis or other active infections
• Severe ventricular dysfunction with ejection fraction < 20%
• Coronary artery disease-related unstable angina
• Inability to tolerate anticoagulation / antiplatelet therapy

Patients with symptomatic aortic stenosis